Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules

Journal of Thoracic Oncology

Volumn 8, Issue 1, 2013, Pages 31-36

  Daly, Shaun ^a   Rinewalt, Daniel ^a   Fhied, Cristina ^a   Basu, Sanjib ^a   Mahon, Brett ^a   Liptay, Michael J ^a   Hong, Edward ^a   Chmielewski, Gary ^a   Yoder, Mark A ^a   Shah, Palmi N ^a   Edell, Eric S ^b   Maldonado, Fabien ^b   Bungum, Aaron O ^b   Borgia, Jeffrey A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Low dose computed tomography screening; Lung cancer; Nodules; Plasma biomarkers; Validation

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; DISEASE MARKER; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INDETERMINATE PULMONARY NODULE; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 84871940924     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827627f8     Document Type: Article

References (26)

1. Henschke CI, Yankelevitz D F, Libby DM, Pasmantier M W, Smith J P, Miettinen OS; International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771.
2. Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, Altorki NK. Tumor size predicts survival within stage IA non-small cell lung cancer. Chest 2003;124:1828-1833.
3. Fontana RS, Sanderson DR, Woolner LB, Taylor W F, Miller WE, Muhm Jr. Lung cancer screening: the Mayo program. J Occup Med 1986;28:746-750.
4. Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of ben-eft from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990;45:26-33.
5. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984;86:44-53.
6. Oken MM, Hocking WG, Kvale PA, et al.; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011;306:1865-1873.
7. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-961.
8. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
9. Goulart BH, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012;10:267-275.
10. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokera-tin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest 2003;124:622-632.
11. Pastor A, Menéndez R, Cremades MJ, Pastor V, Llopis R, Aznar J. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J 1997;10:603-609.
12. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifcation of malignant tumours. J Thorac Oncol 2007;2:706-714.
13. Groome PA, Bolejack V, Crowley JJ, et al.; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classifcation of malignant tumours. J Thorac Oncol 2007;2:694-705.
14. Borgia JA, Basu S, Faber L P, et al. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol 2009;4:338-347.
15. Farlow EC, Vercillo MS, Coon JS, et al. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer 2010;103:1221-1228.
16. Patel K, Farlow EC, Kim AW, et al. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer 2011;129:133-142.
17. Farlow EC, Patel K, Basu S, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010;16:3452-3462.
18. Bach PB, Silvestri GA, Hanger M, et al. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:69S-77S.
19. Henschke CI, Yankelevitz DF. CT screening for lung cancer: update 2007. Oncologist 2008;13:65-78.
20. MacMahon H, Austin JH, Gamsu G, et al.; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237: 395-400.
21. Field JK, Smith RA, Aberle DR, et al.; IASLC CT Screening Workshop 2011 Participants. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012;7:10-19.
22. Patz E F, Caporaso NE, Dubinett SM, et al. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer bio-markers. J Thorac Oncol 2010;5:1502-1506.
23. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011;22:383-389.
24. Murray A, Chapman CJ, Healey G, et al. Technical validation of an auto-antibody test for lung cancer. Ann Oncol 2010;21:1687-1693.
25. Bigbee WL, Gopalakrishnan V, Weissfeld JL, et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol 2012;7:698-708.
26. Bach PB, Mirkin JN, Oliver TK, et al. Benefts and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-2429.